Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mason W Freeman

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 15, 2023
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human SubjectsMason W Freeman, Mary Bond, Brian Murphy, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 20, 2022
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteersMason W Freeman, Mary Bond, Brian Murphy, et al.
Journal of Biopharmaceutical Statistics|August 5, 2005
Nonparametric methods for microarray data based on exchangeability and borrowed powerMei-Ling Ting Lee, G A Whitmore, Harry Björkbacka, et al.
Clinical Pharmacology in Drug Development|February 5, 2024
Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal FunctionMason W Freeman, Yuan-Di Halvorsen, Mary Bond, et al.
Statistical Applications in Genetics and Molecular Biology|May 2, 2006
Generalized rank tests for replicated microarray dataMei-Ling Ting Lee, Robert J Gray, Harry Björkbacka, et al.
The American Journal of Cardiology|January 2, 2007
Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterolDoreen DeFaria Yeh, Mason W Freeman, James B Meigs, et al.
Diabetes, Obesity & Metabolism|June 5, 2019
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adultsYuan-Di Halvorsen, John P Lock, Wenjiong Zhou, et al.
Biochemistry|February 18, 2004
Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1Angeliki Chroni, Tong Liu, Michael L Fitzgerald, et al.
Infection and Immunity|February 26, 2005
Distinct roles of pattern recognition receptors CD14 and Toll-like receptor 4 in acute lung injurySamithamby Jeyaseelan, Hong Wei Chu, Scott K Young, et al.
Diabetes, Obesity & Metabolism|November 22, 2019
A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetesYuan-Di Halvorsen, Geoffrey Walford, Tara Thurber, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 15, 2023
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human SubjectsMason W Freeman, Mary Bond, Brian Murphy, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 20, 2022
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteersMason W Freeman, Mary Bond, Brian Murphy, et al.
Journal of Biopharmaceutical Statistics|August 5, 2005
Nonparametric methods for microarray data based on exchangeability and borrowed powerMei-Ling Ting Lee, G A Whitmore, Harry Björkbacka, et al.
Clinical Pharmacology in Drug Development|February 5, 2024
Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal FunctionMason W Freeman, Yuan-Di Halvorsen, Mary Bond, et al.
Statistical Applications in Genetics and Molecular Biology|May 2, 2006
Generalized rank tests for replicated microarray dataMei-Ling Ting Lee, Robert J Gray, Harry Björkbacka, et al.
The American Journal of Cardiology|January 2, 2007
Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterolDoreen DeFaria Yeh, Mason W Freeman, James B Meigs, et al.
Diabetes, Obesity & Metabolism|June 5, 2019
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adultsYuan-Di Halvorsen, John P Lock, Wenjiong Zhou, et al.
Biochemistry|February 18, 2004
Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1Angeliki Chroni, Tong Liu, Michael L Fitzgerald, et al.
Infection and Immunity|February 26, 2005
Distinct roles of pattern recognition receptors CD14 and Toll-like receptor 4 in acute lung injurySamithamby Jeyaseelan, Hong Wei Chu, Scott K Young, et al.
Diabetes, Obesity & Metabolism|November 22, 2019
A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetesYuan-Di Halvorsen, Geoffrey Walford, Tara Thurber, et al.
Pageof 7